Previous 10 | Next 10 |
Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharm...
LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its commercial stage as BayMedica has been selling cannabichromene (CBC) in bulk. InMed has al...
InMed Pharmaceuticals (NASDAQ: INM) and its subsidiary BayMedica are innovators in the field of rare cannabinoids, making them available for consumer access. InMed specializes in developing a proprietary biosynthesis system to manufacture pharmaceutical-grade cannabinoids that are otherwis...
InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function With neurogenerative diseases affecting millions worldwide and the co...
InMed Pharmaceuticals (NASDAQ:INM): FQ1 GAAP EPS of -$0.25. Cash, cash equivalents and short-term investments were $15.4M Press Release For further details see: InMed Pharmaceuticals reports FQ1 results
VANCOUVER, British Columbia., Nov. 10, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc . (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced financial results for ...
InMed Pharmaceuticals (NASDAQ: INM) , a leader in the manufacturing, development and commercialization of rare cannabinoids, today announced its filing of an international patent application demonstrating neuroprotection and enhanced neuronal function using a rare cannabinoid for the potent...
InMed Pharmaceuticals (NASDAQ:INM) has filed an international patent application for a rare cannabinoid for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others. The Patent Cooperation...
Patent covers novel effects for neurodegenerative diseases Expands InMed’s patent portfolio with incremental rare cannabinoid VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc . (“InMed” or the “Compa...
Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly listed Ginkgo Bioworks Holdings Inc., in what is the largest-ever biotechnology go-public transaction Ginkgo Bioworks is known for its work in the commercial-scale producti...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...